铅中毒大鼠尿激肽释放酶排泄量探讨

本文对亚急性铅中毒大鼠尿激肽释放酶排泄量进行了研究。发现血铅与尿Ka高度相关,大鼠染毒2、3个月尿Ka随血铅水平增高而增高,与对照组比较差异显著。染毒1个月停毒1个月尿Ka略有回降,染毒3个月停毒1个月尿Ka不能恢复,这与血铅水平、病理改变相一致。提示测定尿中Ka含量可直接反映肾内水平.间接反映肾铅水平。该指标较为敏感,无损伤,可考虑作为铅中毒肾损害血压改变的监护指标。     

原因不明的反复流产与激肽释放酶——激肽系统相关性研究进展

激肽释放酶———激肽系统广泛存在于胎儿、胎盘血管内,有研究表明〔1,2〕:绒毛毛细血管内皮细胞内存在激肽原、前激肽释放酶、激肽释放酶。激肽是一种肽类,是由胎盘毛细血管产生,它不仅具有抗凝血、促进纤溶、增加血流量等生物学活性,而且在调节胎盘血流量、代谢产物转运等方面亦发挥重要作用。激肽释放酶—激肽系统除在全身的凝血纤溶系统方面发挥作用外,在生殖领域中亦占有重要地位。最近有报道表明〔3〕:激肽释放酶-激肽系统的蛋白缺乏与反复流产关系密切。此外,针对激肽释放酶-激肽系统蛋白产生的自身抗体也参与反复流产〔4,5〕。1反复…     

PKSI⁃527 对三氯乙烯致敏小鼠体内血浆激肽释放酶⁃激肽系统表达的影响

目的研究三氯乙烯致敏小鼠体内激肽释放酶-激肽系统(KKS)表达水平,探讨职业性三氯乙烯药疹样皮炎(ODMLT)的发病机制。方法将130只雌性6~8周BALB/c小鼠随机分成空白对照组、溶剂对照组、TCE处理组和TCE+PKSI-527处理组;TCE+PKSI-527处理组在17 d和19 d两次激发前24 h腹腔内注射抑制剂PKSI-527;分别于末次激发后24 h、48 h、72 h和7 d处死动物,造模期间实时记录小鼠体重,计算脏器系数,ELISA法检测血浆前激肽释放酶(PK)、高分子量激肽原(HMWK)和缓激肽(BK)水平。结果 TCE处理组的致敏率为40%,以PKSI-527干预后的致敏率为21.67%,TCE致敏组及TCE+PKSI-527组体重与空白对照组相比均明显减少;TCE处理组小鼠48 h、72 h的肝脏系数明显高于空白对照组,而使用PKSI-527干预后小鼠肾脏系数和脾脏系数均有好转。TCE处理组48 h、72 h时致敏小鼠血浆中PK浓度明显高于溶剂对照组及相应的未致敏组,且在72 h时点达到峰值,使用PKSI-527能够显著降低PK浓度。TCE处理组24 h、48 h致敏小鼠血浆中HMWK浓度明显高于溶剂对照组及相应的未致敏组;TCE+PKSI-527处理组48 h时HMWK浓度明显低于相应时段TCE致敏组。血浆BK的变化特点基本与PK和HMWK表达一致。结论 KKS活化可能参与TCE小鼠致敏及脏器免疫损伤过程。     

胰激肽释放酶片对糖尿病早期肾病患者尿蛋白排出的观察

糖尿病肾病 ( DN)是糖尿病全身微血管病变的表现之一 ,其临床发生率为 1 3.5 5 % [1] 。DN是糖尿病的一个严重并发症 ,也是患者死亡的主要原因。所以 ,如何有效预防 DN的发生和发展已受到广泛关注。本研究用胰激肽释放酶片治疗早期 DN,旨在探讨防治 DN的机制。1　材料与方法1 .1　对象　为本院住院的 2型糖尿病肾病早期病人 62例 ,均符合早期 DN的诊断标准 ,即 2 4小时尿蛋白定量 ( 2 4 hup Q)≤ 2 0 0 mg,尿微量白蛋白排泄率( UAR) >2 0 μg/min≤ 2 0 0 μg/min(或 >30 mg/2 4 h≤30 0 mg/2 4 h) ,按随机原则分为两组 ,对照组 2 9…     

脉络宁与胰激肽释放酶合用治疗糖尿病周围神经病变临床观察

自1994年我们对30例糖尿病周围神经病变患者试用脉络宁(脉洛宁注射液:Mailuoning Injection,本药有提高血中纤溶活性,改善微循环,改善高凝状态之用。)及胰激肽释放酶(胰激肽释放酶:Kalliperein,简称TPK;本剂是微循环改善剂。又称血管舒缓素。)治疗、取得满意疗效。1 临床资料 本组病人30例,男12例,女18例,年龄48～72岁,30例均为非胰岛素依赖型糖尿病,多数糖尿病已得到满意控制,出现慢性多发性周围神经病症状,最短者20天,最长者6年,平均2年,2年以内者18例,占60％。2 治疗方法与结果 在管理好血糖的前提下,应用脉络宁20     

人类组织激肽释放酶基因6在子宫颈癌组织中表达的研究

目的 探讨人类组织激肽释放酶基因6(KLK6)在子宫颈癌组织中的表达及意义.方法 以甘油醛-3磷酸脱氢酶(GAPDH)作为内参基因,采用Taqman探针实时荧光定量反转录聚合酶链反应技术分别检测80例子宫颈癌(发生转移40例、未发生转移40例)及40例正常子宫颈组织中KLK6的表达量,并分析子宫颈癌临床病理特征与KLK6表达的关系.结果 KLK6在正常子宫颈组织中表达量[(1.06±0.40)×10-]低于子宫颈癌未转移组织[(4.41±1.70)×10-3]、子宫颈癌转移组织[(32.22±6.70)×10-3],差异均有统计学意义(P＜0.01).子宫颈癌转移组织中Ⅰa、Ⅰb、Ⅱa期KLK6表达量分别为(30.42±5.00)×10-、(31.64±1.30)×10-3、(33.02±8.00)×103,两两比较差异均无统计学意义(P＞0.05);子宫颈癌未转移组织中Ⅰa、Ⅰb、Ⅱa期KLK6表达量分别为(4.12±1.10)×10-3、(4.35±1.30)×10-3、(4.82±1.90)×10-3,两两比较差异均无统计学意义(P＞0.05);但Ⅰa、Ⅰb、Ⅱa期子宫颈癌转移组织中KLK6表达量与同期子宫颈癌未转移组织比较差异均有统计学意义(P＜0.01).结论 KLK6可促进子宫颈癌细胞的增殖,并且参与子宫颈癌的转移过程.     

人组织激肽释放酶4在子宫内膜癌中的表达和预后的关系

目的 探讨人组织激肽释放酶4（ KLK4）在子宫内膜癌中的表达和对预后的影响,为改善子宫内膜癌的预后提供新的思路。方法 免疫组化法检测81例子宫内膜癌、30例不典型增生的子宫内膜和30例正常子宫内膜中KLK4的表达情况,收集患者临床病理资料,结合随访资料做生存分析,并分析KLK4的表达和子宫内膜癌预后的关系。结果 KLK4在正常内膜、不典型增生内膜和子宫内膜癌中的高表达率分别为30％、53％、67％,差异有统计学意义（χ^212．059,P＝0．002）;KLK4的高表达和子宫内膜癌的分化程度及深肌层浸润相关（χ^2=7．985,P＝0．021;χ^2=4．629,P＝0．031）,与年龄、临床分期、淋巴结转移无关（χ^2分别为0．266、1．761、0．277,均P＞0．05）;KLK4高表达组的5年无进展生存率较低表达组更低,差异有统计学意义（P＝0．032）。结论 KLK4的高表达可能与子宫内膜癌细胞的分化和局部侵袭有关,其高表达提示早期复发,KLK4有可能作为预测子宫内膜癌早期复发的标志物。     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

目的探讨人血清中激肽释放酶（KLK）6的水平在上皮性卵巢癌诊断与随访中的价值。方法应用ELISA法检测30例上皮性卵巢癌、20例卵巢良性肿瘤患者和30例健康妇女外周血中KLK6的水平,同时使用化学发光法测定以上人员血清中CA125水平。并检测术后一周、3个月接受随访的12例上皮性卵巢癌患者血清中KLK6和CA125水平。结果术前上皮性卵巢癌患者血清中KLK6水平高于良性组和对照纽（P〈0．05）;KLK6水平与卵巢癌的临床分期、细胞分级、淋巴转移、复发／死亡有关（P〈0．05）,与组织类型无关（P〉0．05）;上皮性卵巢癌患者术后KLK6与CA125水平显著低于术前（P〈0．05）。KLK6对上皮性卵巢癌诊断的敏感度为73．3％,特异度为85．0％,对Ⅰ—Ⅱ和Ⅲ—Ⅳ期卵巢癌诊断的敏感度分别为50．0％,88．9％。结论血清KLK6可作为上皮性卵巢癌实验室诊断、监测和预后的可靠指标之一。     

硫酸镁联合胰激肽释放酶对重度子痫前期孕妇血清NGAL和RBP4表达的影响

目的探讨硫酸镁联合胰激肽释放酶对重度子痫前期孕妇血清中性粒细胞明胶酶相关性脂质运载蛋白(NGAL)和视黄醇结合蛋白4 (RBP4)表达的影响,为临床治疗重度子痫前期提供参考。方法选取2015年10月-2017年1月延安大学附属医院收治的86例重度子痫前期孕妇作为研究对象,采用随机数字法分为对照组和观察组,每组各43例。对照组患者静脉注射硫酸镁治疗,观察组患者在对照组患者治疗的基础上肌内注射胰激肽释放酶治疗。比较两组患者治疗前和治疗后血压、肾功能指标、血小板计数及凝血功能指标,同时比较治疗前后两组血清NGAL和RBP4的表达水平。结果治疗后,观察组收缩压(SBP)、舒张压(DBP)、24 h尿蛋白及血清胱抑素C (Cys-C)水平均明显低于对照组,差异均有统计学意义(均P0. 05)。两组血小板计数(PLT)、血浆纤维蛋白原(FIB)、凝血酶原时间(PT)比较,差异均无统计学意义(均P0. 05)。观察组血清D-二聚体(D-D)水平,血清NGAL、RBP4的表达水平均明显低于对照组,差异均有统计学意义(均P0. 05)。结论硫酸镁联合胰激肽释放酶能有效降低重度子痫前期孕妇血压,保护肾脏功能,改善机体凝血功能,同时能抑制血清NGAL、RBP4水平的表达。     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

ω-3脂肪酸对哺乳期过度喂养大鼠胃组织脑肠肽生长激素释放肽及血清瘦素的影响

目的观察哺乳期过度喂养大鼠断乳后给予ω-3脂肪酸,其胃组织中脑肠肽生长激素释放肽(ghrelin)表达和循环中瘦素(leptin) 浓度的变化,探讨哺乳期过度喂养及断乳后不同饮食干预对成年期代谢综合征的影响及调控作用。 方法 雄性SD大鼠出生后分为正常喂养组(NF组,每窝10只) 和过度喂养组(OF组,每窝3只),出生3周后断乳,OF组分别给予正常饮食（OF+Con）、高脂饮食(OF+HF)及ω-3不饱和脂肪酸饮食（ω-3 PUFAs,OF+ω-3）,NF组给予正常饮食(NF+Con)和高脂饮食(NF+HF)。每周记录体重及摄食量。6和16周时,进行糖耐量试验;酶联免疫吸附法分别测定各组血清leptin、ghrelin及甘油三酯(TG)浓度,实时定量PCR及免疫组织化学法分别测定各组胃组织ghrelin mRNA和蛋白表达浓度。结果 16周时,OF+HF组大鼠能量摄入、体重明显高于NF+HF组(t=－3.453, P=0.014; t=-6.406, P=0.000),血清TG高于OF+Con组（t=4.72, P=0.005）,30 min血糖浓度明显高于其他各组（F=16.249,P=0.000),血清leptin持续高于其他各组,胃组织ghrelin mRNA亦明显高于OF+Con组(t=8.486, P=0.000）,但胃组织ghrelin阳性细胞面积及血清ghrelin差异无统计学意义。16周时OF+Con组血清leptin水平高于NF+Con组（t=-3.274,P=0.031）,OF+HF组血清leptin水平高于OF+Con组（t=3.028,P=0.014)。OF+ω-3组上述指标与正常饮食组相比差异无统计学意义。结论 哺乳期过度喂养对高脂饮食诱导的肥胖和糖脂代谢紊乱更加敏感,更易发生肥胖、糖脂代谢失调,血清leptin和胃组织ghrelin mRNA表达持续增加,加重leptin抵抗和摄食调控的紊乱。ω-3 PUFAs能改善哺乳期过度喂养造成的脂肪组织过度积聚、糖耐量受损、leptin抵抗,维持正常的leptin和ghrelin浓度。